{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:04:15Z","timestamp":1789736655516,"version":"4.0.1"},"reference-count":36,"publisher":"American Veterinary Medical Association (AVMA)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to determine the incidence of postoperative incisional complications following excision of cutaneous and subcutaneous mast cell tumors (MCTs) in dogs receiving neoadjuvant intralesional triamcinolone (NIT) within 30 days of surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of dogs undergoing MCT excision at a tertiary referral hospital from January 2018 to February 2026. Inclusion required histologically confirmed MCT, NIT within 30 days of surgery, and sufficient medical record documentation for outcome assessment. Tumor- and treatment-related variables were recorded. Surgical site complications (SSCs) within 30 days of excision were classified as major or minor. Associations between variables and SSCs were evaluated with nonparametric tests and mixed-effect logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>69 dogs with 78 MCTs were included. Overall SSC incidence was 25% (20 of 78 MCTs; 95% CI, 16.4% to 36.8%), with 90% classified as minor. Surgical site complication incidence was significantly decreased in tumors receiving \u2265 2 injections compared with those receiving a single injection (0% vs 36%). No association was identified between SSC and triamcinolone dose, timing of injection relative to surgery, tumor characteristics, perioperative medications, or bandaging practices. Among tumors with a recorded response, 65% decreased in size, with a median reduction of 40%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NIT administration within 30 days of excision was not associated with an increased incidence of short-term postoperative incisional complications in dogs with cutaneous or subcutaneous MCTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>NIT may be considered as an adjunct in management of canine MCTs to reduce tumor size and peritumoral inflammation while maintaining an acceptable SSC rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/javma.26.04.0311","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:39:11Z","timestamp":1783532351000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant intralesional triamcinolone is not associated with increased incidence of surgical site complications in dogs with cutaneous and subcutaneous mast cell tumors"],"prefix":"10.2460","volume":"264","author":[{"given":"Daniel R.","family":"Gruber","sequence":"first","affiliation":[{"name":"BluePearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Doornink","sequence":"additional","affiliation":[{"name":"BluePearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Urie","sequence":"additional","affiliation":[{"name":"BluePearl Pittsburgh North, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"3","key":"ref1","series-title":"Vet Clin North Am Small Anim Pract","first-page":"473","article-title":"Mast cell tumors in the dog","volume":"33","author":"London CA","year":"2003","unstructured":"London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract. 2003;33(3):473-489, v. doi:10.1016\/S0195-5616(03)00003-2"},{"issue":"3","key":"ref2","series-title":"Vet Comp Oncol","first-page":"e1","article-title":"European consensus document on mast cell tumours in dogs and cats","volume":"10","author":"Blackwood L","year":"2012","unstructured":"Blackwood L, Murphy S, Buracco P,  European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012;10(3):e1-e29. doi:10.1111\/j.1476-5829.2012.00341.x"},{"issue":"1","key":"ref3","series-title":"Vet Pathol","first-page":"147","article-title":"Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior","volume":"48","author":"Kiupel M","year":"2011","unstructured":"Kiupel M, Webster JD, Bailey KL,  Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48(1):147-155. doi:10.1177\/0300985810386469"},{"issue":"5","key":"ref4","series-title":"J Am Anim Hosp Assoc","first-page":"458","article-title":"Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases","volume":"38","author":"Michels GM","year":"2002","unstructured":"Michels GM, Knapp DW, DeNicola DB, Glickman N, Bonney P. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc. 2002;38(5):458-466. doi:10.5326\/0380458"},{"issue":"1","key":"ref5","series-title":"J Am Vet Med Assoc","first-page":"91","article-title":"Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004)","volume":"228","author":"Mullins MN","year":"2006","unstructured":"Mullins MN, Dernell WS, Withrow SJ, Ehrhart EJ, Thamm DH, Lana SE. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc. 2006;228(1):91-95. doi:10.2460\/javma.228.1.91"},{"issue":"4","key":"ref6","series-title":"J Vet Intern Med","first-page":"933","article-title":"Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002)","volume":"20","author":"S\u00e9guin B","year":"2006","unstructured":"S\u00e9guin B, Besancon MF, McCallan JL,  Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med. 2006;20(4):933-940. doi:10.1892\/0891-6640(2006)20[933:RRCOAC]2.0.CO;2"},{"issue":"2","key":"ref7","series-title":"J Am Vet Med Assoc","first-page":"210","article-title":"Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs","volume":"228","author":"Fulcher RP","year":"2006","unstructured":"Fulcher RP, Ludwig LL, Bergman PJ, Newman SJ, Simpson AM, Patnaik AK. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2006;228(2):210-215. doi:10.2460\/javma.228.2.210"},{"issue":"5","key":"ref8","series-title":"J Am Vet Med Assoc","first-page":"567","article-title":"Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs","volume":"256","author":"Chu ML","year":"2020","unstructured":"Chu ML, Hayes GM, Henry JG, Oblak ML. Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2020;256(5):567-572. doi:10.2460\/javma.256.5.567"},{"issue":"1","key":"ref9","series-title":"BMC Vet Res","first-page":"5","article-title":"A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs","volume":"16","author":"Selmic LE","year":"2020","unstructured":"Selmic LE, Ruple A. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Vet Res. 2020;16(1):5. doi:10.1186\/s12917-019-2227-8"},{"issue":"2","key":"ref10","series-title":"J Vet Med Sci","first-page":"230","article-title":"Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs","volume":"83","author":"Itoh T","year":"2021","unstructured":"Itoh T, Kojimoto A, Uchida K, Chambers J, Shii H. Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs. J Vet Med Sci. 2021;83(2):230-233. doi:10.1292\/jvms.20-0281"},{"issue":"4","key":"ref11","series-title":"Vet Comp Oncol","first-page":"604","article-title":"Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome","volume":"19","author":"Saunders H","year":"2021","unstructured":"Saunders H, Thomson MJ, O\u2019Connell K, Bridges JP, Chau L. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome. Vet Comp Oncol. 2021;19(4):604-615. doi:10.1111\/vco.12630"},{"issue":"3","key":"ref12","series-title":"Vet Comp Oncol","first-page":"156","article-title":"Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004)","volume":"5","author":"Camps-Palau MA","year":"2007","unstructured":"Camps-Palau MA, Leibman NF, Elmslie R,  Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp Oncol. 2007;5(3):156-167. doi:10.1111\/j.1476-5829.2006.00125.x"},{"issue":"3","key":"ref13","series-title":"Vet Comp Oncol","first-page":"409","article-title":"Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumours and early nodal metastasis undergoing surgery","volume":"18","author":"Marconato L","year":"2020","unstructured":"Marconato L, Stefanello D, Kiupel M,  Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumours and early nodal metastasis undergoing surgery. Vet Comp Oncol. 2020;18(3):409-415. doi:10.1111\/vco.12566"},{"issue":"2","key":"ref14","series-title":"J Am Anim Hosp Assoc","first-page":"124","article-title":"Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors","volume":"40","author":"Davies DR","year":"2004","unstructured":"Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc. 2004;40(2):124-130. doi:10.5326\/0400124"},{"issue":"3","key":"ref15","series-title":"Vet Comp Oncol","first-page":"132","article-title":"Treatment of canine mast cell tumours with prednisolone and radiotherapy","volume":"2","author":"Dobson J","year":"2004","unstructured":"Dobson J, Cohen S, Gould S. Treatment of canine mast cell tumours with prednisolone and radiotherapy. Vet Comp Oncol. 2004;2(3):132-141. doi:10.1111\/j.1476-5810.2004.00048.x"},{"issue":"12","key":"ref16","series-title":"Can Vet J","first-page":"1326","article-title":"Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors","volume":"60","author":"Hay JK","year":"2019","unstructured":"Hay JK, Larson VS. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. Can Vet J. 2019;60(12):1326-1330."},{"issue":"6","key":"ref17","series-title":"J Small Anim Pract","first-page":"284","article-title":"Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases","volume":"50","author":"Taylor F","year":"2009","unstructured":"Taylor F, Gear R, Hoather T, Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. J Small Anim Pract. 2009;50(6):284-289. doi:10.1111\/j.1748-5827.2009.00732.x"},{"issue":"2","key":"ref18","series-title":"Vet Comp Oncol","first-page":"138","article-title":"A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours","volume":"8","author":"Rassnick KM","year":"2010","unstructured":"Rassnick KM, Bailey DB, Russell DS,  A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol. 2010;8(2):138-152. doi:10.1111\/j.1476-5829.2010.00217.x"},{"issue":"1","key":"ref19","series-title":"J Am Anim Hosp Assoc","first-page":"14","article-title":"Adjuvant CCNU (Lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors","volume":"45","author":"Hosoya K","year":"2009","unstructured":"Hosoya K, Kisseberth WC, Alvarez FJ,  Adjuvant CCNU (Lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc. 2009;45(1):14-18. doi:10.5326\/0450014"},{"issue":"3","key":"ref20","series-title":"Vet Comp Oncol","first-page":"168","article-title":"Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours","volume":"5","author":"Hayes A","year":"2007","unstructured":"Hayes A, Adams V, Smith K, Maglennon G, Murphy S. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet Comp Oncol. 2007;5(3):168-176. doi:10.1111\/j.1476-5829.2007.00135.x"},{"issue":"6","key":"ref21","series-title":"J Vet Intern Med","first-page":"406","article-title":"Response of canine mast cell tumors to treatment with oral prednisone","volume":"8","author":"McCaw DL","year":"1994","unstructured":"McCaw DL, Miller MA, Ogilvie GK,  Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med. 1994;8(6):406-408. doi:10.1111\/j.1939-1676.1994.tb03259.x"},{"issue":"1","key":"ref22","series-title":"Can Vet J","first-page":"45","article-title":"The effect of prednisone on histologic and gross characteristics in canine mast cell tumors","volume":"62","author":"Linde KJ","year":"2021","unstructured":"Linde KJ, Stockdale SL, Mison MB, Perry JA. The effect of prednisone on histologic and gross characteristics in canine mast cell tumors. Can Vet J. 2021;62(1):45-50."},{"issue":"1","key":"ref23","series-title":"J Am Vet Med Assoc","first-page":"53","article-title":"Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs","volume":"232","author":"Stanclift RM","year":"2008","unstructured":"Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2008;232(1):53-62. doi:10.2460\/javma.232.1.53"},{"issue":"1","key":"ref24","series-title":"Cell Death Differ","first-page":"6","article-title":"Recent insights into the mechanism of glucocorticosteroid-induced apoptosis","volume":"9","author":"Distelhorst CW","year":"2002","unstructured":"Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 2002;9(1):6-19. doi:10.1038\/sj.cdd.4400969"},{"issue":"3","key":"ref25","series-title":"Am J Surg","first-page":"410","article-title":"Corticosteroids and wound healing: clinical considerations in the perioperative period","volume":"206","author":"Wang AS","year":"2013","unstructured":"Wang AS, Armstrong EJ, Armstrong AW. Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg. 2013;206(3):410-417. doi:10.1016\/j.amjsurg.2012.11.018"},{"key":"ref26","series-title":"Textbook of Veterinary Internal Medicine: Diseases of the Dog and the Cat","first-page":"602","article-title":"Glucocorticoid therapy","author":"Cohn L","year":"2010","unstructured":"Cohn L. Glucocorticoid therapy. In: Ettinger SJ, Feldman E, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and the Cat. 7th ed. Elsevier Saunders; 2010:602\u2013608."},{"issue":"1","key":"ref27","series-title":"J Am Vet Med Assoc","first-page":"84","article-title":"Safety and efficacy of intralesional triamcinolone administration for treatment of mast cell tumors in dogs: 23 cases (2005-2011)","volume":"252","author":"Case A","year":"2018","unstructured":"Case A, Burgess K. Safety and efficacy of intralesional triamcinolone administration for treatment of mast cell tumors in dogs: 23 cases (2005-2011). J Am Vet Med Assoc. 2018;252(1):84-91. doi:10.2460\/javma.252.1.84"},{"issue":"6","key":"ref28","series-title":"J Vet Intern Med","first-page":"3162","article-title":"Response to tigilanol tiglate in dogs with mast cell tumors","volume":"38","author":"Musser ML","year":"2024","unstructured":"Musser ML, Jones PD, Goodson TL, Roof E, Johannes CM. Response to tigilanol tiglate in dogs with mast cell tumors. J Vet Intern Med. 2024;38(6):3162-3169. doi:10.1111\/jvim.17211"},{"issue":"S1","key":"ref29","series-title":"J Am Vet Med Assoc","first-page":"S88","article-title":"Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications","volume":"260","author":"Iodence AE","year":"2021","unstructured":"Iodence AE, Wallace ML, Grimes JA, Schmiedt CW. Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications. J Am Vet Med Assoc. 2021;260(S1):S88-S95. doi:10.2460\/javma.20.09.0488"},{"issue":"9","key":"ref30","series-title":"J Small Anim Pract","first-page":"469","article-title":"Mast cell tumour and cutaneous histiocytoma excision wound healing in general practice","volume":"52","author":"Killick DR","year":"2011","unstructured":"Killick DR, Rowlands AM, Burrow RD,  Mast cell tumour and cutaneous histiocytoma excision wound healing in general practice. J Small Anim Pract. 2011;52(9):469-475. doi:10.1111\/j.1748-5827.2011.01093.x"},{"issue":"7","key":"ref31","series-title":"J Am Vet Med Assoc","first-page":"741","article-title":"Marginal excision of cutaneous mast cell tumors in dogs was not associated with a higher rate of complications or prolonged wound healing than marginal excision of soft tissue sarcomas","volume":"260","author":"Cockburn E","year":"2022","unstructured":"Cockburn E, Janovec J, Solano MA, L\u2019Eplattenier H. Marginal excision of cutaneous mast cell tumors in dogs was not associated with a higher rate of complications or prolonged wound healing than marginal excision of soft tissue sarcomas. J Am Vet Med Assoc. 2022;260(7):741-746. doi:10.2460\/javma.21.05.0235"},{"issue":"1","key":"ref32","series-title":"J Small Anim Pract","first-page":"67","article-title":"Clinical, pathological and prognostic features of surgically excised cutaneous and subcutaneous digital and distal limb mast cell tumours in dogs","volume":"67","author":"Erickson AK","year":"2026","unstructured":"Erickson AK, Tremolada G, Sztukowski KE, Thamm DH, Husbands BD. Clinical, pathological and prognostic features of surgically excised cutaneous and subcutaneous digital and distal limb mast cell tumours in dogs. J Small Anim Pract. 2026;67(1):67-76. doi:10.1111\/jsap.70020"},{"issue":"2","key":"ref33","series-title":"Vet Comp Oncol","first-page":"311","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc AK","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT,  Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111\/vco.12677"},{"issue":"9","key":"ref34","series-title":"Am J Vet Res","first-page":"1234","article-title":"Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses","volume":"72","author":"Soma LR","year":"2011","unstructured":"Soma LR, Uboh CE, You Y, Guan F, Boston RC. Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. Am J Vet Res. 2011;72(9):1234-1242. doi:10.2460\/ajvr.72.9.1234"},{"issue":"1","key":"ref35","series-title":"J Vet Intern Med","first-page":"aalaf081","article-title":"Outcome of dogs with low- and high-grade mast cell tumors treated with electrochemotherapy","volume":"40","author":"Ojeda J","year":"2026","unstructured":"Ojeda J, Caixeta ML, Mieres M, Sandoval P, Ortloff A. Outcome of dogs with low- and high-grade mast cell tumors treated with electrochemotherapy. J Vet Intern Med. 2026;40(1):aalaf081. doi:10.1093\/jvimsj\/aalaf081"},{"issue":"1","key":"ref36","series-title":"J Vet Intern Med","first-page":"135","article-title":"Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors","volume":"26","author":"Carlsten KS","year":"2012","unstructured":"Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med. 2012;26(1):135-141. doi:10.1111\/j.1939-1676.2011.00851.x"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/264\/10\/javma.26.04.0311.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/264\/10\/javma.26.04.0311.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/264\/10\/javma.26.04.0311.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:14:58Z","timestamp":1789733698000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/264\/10\/javma.26.04.0311.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":36,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.2460\/javma.26.04.0311","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}